NEW YORK, September 27, 2022 (GLOBE NEWSWIRE) -- Dante Genomics, a global leader in genomics and precision medicine, is pleased to announce that the Company’s co-founder and CEO Andrea Riposati will be an opening speaker on Tuesday, September 27, 2022 at the United Nations General Assembly (UNGA) Science Summit, where he will unveil the Company’s
Ireland Digital Health Population Genomics Living Lab.
“Personalized medicine needs personalized data, and the whole genome is the most personalized data available to an individual to inform better healthcare decisions,” said Andrea Riposati, CEO of Dante Genomics. “We are thrilled to launch two Living Labs focused in Ireland and implement our model to sequence your whole genome once and query it for a lifetime.”
The UNGA Science Summit discussed global standards to leapfrog digital health adoption by countries and healthcare systems across five continents, highlighting the need for private organizations to drive change in public healthcare systems.
“Whole genome sequencing in clinical care can deliver a tenfold improvement in the lives of individuals, and it is the first step toward driving personalized medicine in healthcare,” said Martin Curley, Director of Digital Transformation and Open Innovation at the Health Service Executive (HSE). “Exciting living labs will demonstrate the importance of private and public
entities working together to make whole genome sequencing the gold standard of clinical care in Ireland.”
The living labs will launch in October 2022, and they will begin testing individuals in Ireland with diagnoses in two specific rare disease areas. The data coming out of these living labs will demonstrate the potential for new initiatives, offering Ireland and other countries the ability to leverage Dante Genomics’ advanced platform to offer end-to-end solutions without the data and
samples needing to leave the country.
About Dante Genomics
Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.